Department of Chemical Sciences, Wyeth, CN 8000, Princeton, NJ 08543-8000, USA.
Bioorg Med Chem Lett. 2010 Apr 1;20(7):2068-73. doi: 10.1016/j.bmcl.2010.02.075. Epub 2010 Feb 23.
The proteolytic enzyme beta-secretase (BACE1) plays a central role in the synthesis of the pathogenic beta-amyloid in Alzheimer's disease. Recently, we reported small molecule acylguanidines as potent BACE1 inhibitors. However, many of these acylguanidines have a high polar surface area (e.g. as measured by the topological polar surface area or TPSA), which is unfavorable for crossing the blood-brain barrier. Herein, we describe the identification of the 2-aminopyridine moiety as a bioisosteric replacement of the acylguanidine moiety, which resulted in inhibitors with lower TPSA values and superior brain penetration. X-ray crystallographic studies indicated that the 2-aminopyridine moiety interacts directly with the catalytic aspartic acids Asp32 and Asp228 via a hydrogen-bonding network.
蛋白水解酶β-分泌酶(BACE1)在阿尔茨海默病中致病性β-淀粉样蛋白的合成中起着核心作用。最近,我们报道了小分子酰基胍作为有效的 BACE1 抑制剂。然而,这些酰基胍中的许多具有高极性表面积(例如,通过拓扑极性表面积或 TPSA 来测量),这不利于穿过血脑屏障。在此,我们描述了将 2-氨基吡啶部分鉴定为酰基胍部分的生物等排体替代物,这导致了具有更低 TPSA 值和更好的脑穿透性的抑制剂。X 射线晶体学研究表明,2-氨基吡啶部分通过氢键网络直接与催化天冬氨酸 Asp32 和 Asp228 相互作用。